Core Viewpoint - The announcement indicates that the drug candidate BPI-572270, developed by the company's wholly-owned subsidiary Jingyao Biotech, has received approval from the National Medical Products Administration for clinical trials in patients with advanced malignant solid tumors [1] Group 1: Drug Development - BPI-572270 is a new molecular entity that the company has independently developed and holds complete intellectual property rights [1] - It is characterized as a novel and potent pan-RAS non-degradable molecular glue inhibitor [1] Group 2: Mechanism of Action - The mechanism of action involves inducing the chaperone protein Cyclophilin A (CYPA) to bind to activated mutant RAS proteins, leading to conformational changes in RAS proteins [1] - This process prevents RAS proteins from binding to downstream signaling proteins, such as cRAF, thereby blocking the MAPK signaling pathways responsible for tumor growth [1]